PUBLISHER: The Business Research Company | PRODUCT CODE: 1409455

PUBLISHER: The Business Research Company | PRODUCT CODE: 1409455

GLP-1 Receptor Agonist Global Market Report 2024

Published: Pre-Order

PAGES: 200 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

Description

“GLP-1 Receptor Agonist Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glp-1 receptor agonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glp-1 receptor agonist? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The glp-1 receptor agonist market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Exenatide; Liraglutide; Dulaglutide; Lixisenatide; Other Drugs
2) By Route Of Administration: Parenteral; Oral
3) By End Users: Hospitals; Surgical Clinics; Other Users
Companies Mentioned: Novo Nordisk A/S; Sanofi SA; Eli Lilly and Company; AstraZeneca Inc.; Boehringer Ingelheim International GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

A GLP-1 receptor agonist is a type of medication designed to stimulate insulin release when blood glucose levels are elevated and to inhibit glucagon secretion in the presence of low blood glucose conditions. These medications are primarily employed in the treatment of type 2 diabetes mellitus.

The main drug class of GLP-1 receptor agonists includes liraglutide, dulaglutide, lixisenatide, and others. Liraglutide, for instance, is a GLP-1 receptor agonist that facilitates the release of an appropriate amount of insulin from the pancreas in response to elevated blood sugar levels. These medications are administered through parenteral and oral routes, commonly utilized in settings such as hospitals, surgical clinics, and other medical facilities.

The GLP-1 receptor agonist market research report is one of a series of new reports from The Business Research Company that provides GLP-1 receptor agonist market statistics, including GLP-1 receptor agonist industry global market size, regional shares, competitors with GLP-1 receptor agonist market share, detailed GLP-1 receptor agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the GLP-1 receptor agonist industry. This GLP-1 receptor agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The glp-1 receptor agonist market size has grown steadily in recent years. It will grow from $13.1 billion in 2023 to $13.74 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historical period can be attributed to the increasing prevalence of diabetes, the clinical efficacy of treatments, growing patient awareness and acceptance, global health initiatives, and the preference among patients for injectable therapies.

The glp-1 receptor agonist market size is expected to see strong growth in the next few years. It will grow to $16.82 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the increasing emphasis on lifestyle management, the adoption of personalized medicine approaches, the expansion of indications, the development of next-generation products, and integration into combination therapies. Major trends expected in the forecast period include the introduction of oral formulations, a focus on combination therapies, strategic partnerships and collaborations, considerations for reimbursement policies and access, and the adoption of patient-centric approaches.

The growth of the GLP-1 receptor agonist market is anticipated to be fueled by the increasing prevalence of diabetes. Diabetes is a chronic condition resulting from inadequate insulin production by the pancreas or ineffective use of the produced insulin by the body. High blood sugar is a characteristic symptom of this metabolic disorder known as diabetes mellitus. GLP-1 receptor agonists play a crucial role in diabetes management by stimulating the production of insulin, thereby lowering blood sugar levels. The International Diabetes Federation reported in December 2021 that approximately 537 million adults globally are living with diabetes, and this number is expected to rise to 643 million by 2030. Hence, the escalating prevalence of diabetes is a significant factor driving the growth of the GLP-1 receptor agonist market.

The growth of the GLP-1 receptor agonist market is also expected to be boosted by the increasing cases of obesity. Obesity, a medical condition characterized by excessive body fat accumulation, is associated with various health risks. GLP-1 receptor agonists have shown effectiveness in treating obesity by mimicking the effects of the naturally occurring hormone GLP-1, which regulates appetite and blood sugar levels. According to the World Health Organization's March 2022 report, over 1 billion individuals globally are affected by obesity, including 650 million adults, 340 million adolescents, and 39 million children, with this number continuing to rise. It is estimated that around 167 million people may experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is contributing to the growth of the GLP-1 receptor agonist market.

A key trend gaining momentum in the GLP-1 receptor agonist market is product innovation, with major companies focusing on developing innovative solutions to strengthen their market position. For instance, in May 2022, Eli Lilly and Company launched Mounjaro, an FDA-approved GIP and GLP-1 receptor agonist designed using a single molecule to activate the body's receptors for incretin hormones. This product is available as a pen auto-injector with a pre-attached, hidden needle, providing convenience for patients.

Major companies in the GLP-1 receptor agonist market are concentrating on developing sustained-release GLP-1 receptor agonists to gain a competitive edge. Sustained-release GLP-1 receptor agonists slowly release the medication into the bloodstream, allowing for longer-lasting effects and less frequent injections compared to traditional GLP-1 receptor agonists. Mitsubishi Tanabe Pharma Corporation launched Mounjaro 2.5 mg or 5 mg Ateos in April 2023, which is the world's first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes.

In February 2022, Sanofi S.A. strengthened its position in the market by acquiring Amunix Pharmaceuticals Inc., a US-based immuno-oncology company developing GLP-1 receptor agonists and transformative therapies for cancer. The acquisition is expected to provide Sanofi access to various products and technologies, including next-generation conditionally activated biologics.

Major companies operating in the glp-1 receptor agonist market report are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., 9 Meters Biopharma Inc., Intarcia Therapeutics Inc., Amylin Pharmaceuticals Inc., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., CymaBay Therapeutics Inc., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., Genentech Inc., GlaxoSmithKline plc, HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Kowa Company Ltd., LG Chem Ltd., Ligand Pharmaceuticals Incorporated, Merck & Co. Inc., Novartis AG .

North America was the largest region in the GLP-1 receptor agonist market in 2023. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The GLP-1 receptor agonist market consists of sales of dulaglutide, bydureon b-cise, exenatide, and semaglutide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r10993

1. Executive Summary

2. GLP-1 Receptor Agonist Market Characteristics

3. GLP-1 Receptor Agonist Market Trends And Strategies

4. GLP-1 Receptor Agonist Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global GLP-1 Receptor Agonist Market Size and Growth

5.1. Global GLP-1 Receptor Agonist Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global GLP-1 Receptor Agonist Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global GLP-1 Receptor Agonist Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. GLP-1 Receptor Agonist Market Segmentation

6.1. Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Exenatide
Liraglutide
Dulaglutide
Lixisenatide
Other Drugs
6.2. Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Parenteral
Oral
6.3. Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Surgical Clinics
Other Users

7. GLP-1 Receptor Agonist Market Regional And Country Analysis

7.1. Global GLP-1 Receptor Agonist Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global GLP-1 Receptor Agonist Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific GLP-1 Receptor Agonist Market

8.1. Asia-Pacific GLP-1 Receptor Agonist Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China GLP-1 Receptor Agonist Market

9.1. China GLP-1 Receptor Agonist Market Overview
9.2. China GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India GLP-1 Receptor Agonist Market

10.1. India GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan GLP-1 Receptor Agonist Market

11.1. Japan GLP-1 Receptor Agonist Market Overview
11.2. Japan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia GLP-1 Receptor Agonist Market

12.1. Australia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia GLP-1 Receptor Agonist Market

13.1. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea GLP-1 Receptor Agonist Market

14.1. South Korea GLP-1 Receptor Agonist Market Overview
14.2. South Korea GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe GLP-1 Receptor Agonist Market

15.1. Western Europe GLP-1 Receptor Agonist Market Overview
15.2. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK GLP-1 Receptor Agonist Market

16.1. UK GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany GLP-1 Receptor Agonist Market

17.1. Germany GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France GLP-1 Receptor Agonist Market

18.1. France GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy GLP-1 Receptor Agonist Market

19.1. Italy GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain GLP-1 Receptor Agonist Market

20.1. Spain GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe GLP-1 Receptor Agonist Market

21.1. Eastern Europe GLP-1 Receptor Agonist Market Overview
21.2. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia GLP-1 Receptor Agonist Market

22.1. Russia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America GLP-1 Receptor Agonist Market

23.1. North America GLP-1 Receptor Agonist Market Overview
23.2. North America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA GLP-1 Receptor Agonist Market

24.1. USA GLP-1 Receptor Agonist Market Overview
24.2. USA GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada GLP-1 Receptor Agonist Market

25.1. Canada GLP-1 Receptor Agonist Market Overview
25.2. Canada GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America GLP-1 Receptor Agonist Market

26.1. South America GLP-1 Receptor Agonist Market Overview
26.2. South America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil GLP-1 Receptor Agonist Market

27.1. Brazil GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East GLP-1 Receptor Agonist Market

28.1. Middle East GLP-1 Receptor Agonist Market Overview
28.2. Middle East GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa GLP-1 Receptor Agonist Market

29.1. Africa GLP-1 Receptor Agonist Market Overview
29.2. Africa GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. GLP-1 Receptor Agonist Market Competitive Landscape And Company Profiles

30.1. GLP-1 Receptor Agonist Market Competitive Landscape
30.2. GLP-1 Receptor Agonist Market Company Profiles
- 30.2.1. Novo Nordisk A/S
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Sanofi SA
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Eli Lilly and Company
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AstraZeneca Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Boehringer Ingelheim International GmbH
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global GLP-1 Receptor Agonist Market Competitive Benchmarking

32. Global GLP-1 Receptor Agonist Market Competitive Dashboard

33. Key Mergers And Acquisitions In The GLP-1 Receptor Agonist Market

34. GLP-1 Receptor Agonist Market Future Outlook and Potential Analysis

34.1 GLP-1 Receptor Agonist Market In 2028 - Countries Offering Most New Opportunities
34.2 GLP-1 Receptor Agonist Market In 2028 - Segments Offering Most New Opportunities
34.3 GLP-1 Receptor Agonist Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ